Cardiology Societies Back Expanded Medicare Coverage for Valve Replacement

In a significant moment for structural heart medicine, three of the world’s leading cardiovascular organizations have come together to endorse a major shift in how Medicare covers one of the most transformative cardiac procedures of the past two decades. The American College of Cardiology, The Society of Thoracic Surgeons, and the Society for Cardiovascular Angiography and Interventions have jointly issued a formal statement responding to the transcatheter aortic valve replacement national coverage determination released by the Centers for Medicare and Medicaid Services. The statement reflects both gratitude for expanded patient access and a firm insistence that the quality infrastructure underpinning the procedure’s success must not be diluted as its reach widens.

Transcatheter aortic valve replacement, widely known as TAVR, has fundamentally redefined the treatment of severe aortic stenosis, a progressive narrowing of the heart’s aortic valve that once carried a dismal prognosis for patients too frail to survive open-heart surgery. Rather than replacing the valve through a sternotomy and cardiopulmonary bypass, TAVR delivers a collapsible bioprosthetic valve through a catheter, typically entered at the femoral artery, and positions it within the diseased native valve. The technique has evolved from a salvage therapy for inoperable patients into a standard option across the entire risk spectrum, supported by an accumulating body of randomized trial evidence demonstrating durability and survival benefit comparable to, and in some populations superior to, surgical valve replacement.

The joint statement opens with explicit appreciation for the federal agency’s willingness to modernize its coverage framework. “The American College of Cardiology, the Society of Thoracic Surgeons, and the Society for Cardiovascular Angiography and Interventions appreciate CMS’s efforts to evolve Medicare coverage for TAVR and enhancing access to more patients as the evidence supporting this therapy continues to grow,” the statement declares. For years, patient advocates and clinicians have argued that earlier national coverage determination requirements, which restricted reimbursement largely to facilities meeting specific volume thresholds, created geographic barriers that left many elderly Americans traveling long distances or forgoing treatment altogether for a disease whose five-year untreated survival rivals many advanced cancers.

Yet the societies were equally emphatic that expanded access must not come at the cost of the disciplined, multidisciplinary model that made TAVR one of the most closely studied and carefully monitored therapies in cardiovascular medicine. “As TAVR expands into new patient populations, it is critical to preserve the quality framework that has contributed to its success,” the statement continues. At the center of that framework sits the Heart Team, the collaborative unit of interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiologists, and advanced practice providers who jointly evaluate every candidate for transcatheter therapy. This team-based approach, embedded in professional society guidelines and prior coverage requirements, ensures that each patient receives an individualized assessment of anatomical suitability, procedural risk, and the relative merits of surgical versus catheter-based valve replacement.

The statement identifies several pillars as non-negotiable as coverage evolves: preservation of the Heart Team, continued collaboration across specialties, collection of real-world evidence, systematic outcomes monitoring, and continuous quality improvement. “The preservation of the Heart Team, continued collaboration across specialties, collection of Real-World Evidence, outcomes monitoring, and continuous quality improvement are the foundation of ensuring and improving outcomes for our patients with severe aortic stenosis,” the societies wrote. From a technical standpoint, this vigilance is well founded. TAVR outcomes are highly sensitive to case selection and procedural expertise, with known complications including paravalvular regurgitation, conduction disturbances requiring permanent pacemaker implantation, vascular access injuries, and, in earlier-generation devices, stroke. Careful imaging with computed tomographic angiography and echocardiography, alongside refined valve designs and delivery systems, has steadily reduced these risks, but only within programs that maintain rigorous procedural volume and data review.

Central to the societies’ position is the role of national registries, which have served as the backbone of TAVR surveillance in the United States since the procedure first received approval. “Participation in national registries, externally benchmarked quality programs and rigorous outcomes reporting remain essential to preserving the high standards of care that have defined TAVR’s success,” the statement affirms. The societies committed explicitly to their continued support of the STS/ACC Transcatheter Valve Therapy Registry, the national data infrastructure that captures procedural details, in-hospital outcomes, and longitudinal follow-up for essentially every TAVR performed in American centers. “The societies will continue to support the STS/ACC TVT Registry and other quality initiatives that promote evidence generation, patient safety, continuous improvement and health care value across the cardiovascular community,” they wrote.

The registry model has proven its scientific worth repeatedly. Data drawn from the TVT Registry have informed valve selection strategies, illuminated sex-specific differences in procedural outcomes, quantified real-world rates of pacemaker dependency and readmission, and provided the pragmatic evidence base that regulators have relied upon at each successive expansion of the coverage determination. Observational registry research complements randomized controlled trials by capturing the full heterogeneity of clinical practice, including elderly patients with frailty, bicuspid anatomy, and multimorbidity who are systematically underrepresented in pivotal trials. For a procedure now performed tens of thousands of times annually in the United States, this continuous feedback loop between bedside practice and aggregate data represents one of the most mature examples of learning health system infrastructure in any field of medicine.

The joint statement carries the signatures of the three organizations’ sitting presidents, underscoring the unified front across specialties that have historically approached valve therapy from different vantage points. Roxana Mehran, MD, FACC, president of the American College of Cardiology; Vinay Badhwar, MD, FACS, FACC, president of The Society of Thoracic Surgeons; and J. Dawn Abbott, MD, MSCAI, president of the Society for Cardiovascular Angiography and Interventions, lent their names to a document that deliberately bridges the surgical and interventional communities. That unity is itself noteworthy. Surgical aortic valve replacement remains a durable and appropriate choice for many patients, and the cardiothoracic surgery community has been an essential partner in TAVR’s development rather than a bystander to its rise, co-owning the registries, co-authoring the guidelines, and staffing the Heart Teams at every established program.

The American College of Cardiology, with a membership exceeding 60,000 cardiovascular professionals across more than 140 countries, brings to the effort its extensive registry and accreditation apparatus, including the NCDR family of quality registries. The Society of Thoracic Surgeons, founded in 1964 and representing more than 8,000 cardiothoracic surgeons, researchers, and allied professionals, has long operated its own national surgical databases that pioneered risk-adjusted outcomes reporting in cardiac surgery. The Society for Cardiovascular Angiography and Interventions, established in 1978 as the primary nonprofit society for invasive and interventional cardiology, contributes the procedural expertise of its more than 5,000 members. Together, these organizations collectively steward the educational standards, credentialing pathways, and data systems that determine how TAVR is practiced nationwide.

As Medicare’s revised national coverage determination takes effect, the practical stakes are considerable for patients, hospitals, and the broader trajectory of structural heart intervention. Expanded eligibility promises that more of the growing population of Americans with severe symptomatic aortic stenosis can receive a minimally invasive valve replacement close to home, while the societies’ insistence on Heart Team evaluation, registry participation, and transparent outcomes reporting aims to ensure that the procedure’s impressive evidence-based track record translates faithfully into everyday community practice. The statement ultimately reads less like celebration and more like stewardship: an acknowledgment that a therapy once confined to a handful of pioneering centers has matured into a population-scale treatment, and that the disciplines of measurement, collaboration, and accountability that carried it from first-in-human trials to standard of care must now scale alongside it.

Beyond the immediate policy debate, the statement arrives at a time when the demographic pressure on valve care continues to intensify. Calcific aortic stenosis is fundamentally a disease of aging, driven by progressive leaflet calcification that shares several mechanistic features with atherosclerosis, including lipid accumulation, inflammation, and active bone-like mineral deposition. As life expectancy rises, the prevalence of severe symptomatic disease is expected to grow steadily, placing sustained demand on both surgical and transcatheter capacity and making coverage policy a genuine population health question rather than a narrow reimbursement matter.

The national coverage determination mechanism itself deserves context. Under Medicare rules, CMS must generally decide whether a service is reasonable and necessary for beneficiaries nationwide, and for novel technologies it has historically used coverage with evidence development, linking payment to registry enrollment or clinical study participation. TAVR became one of the most prominent applications of this model, with successive determinations tracking the expanding randomized evidence and conditioning coverage on facility requirements, Heart Team evaluation, and shared decision-making aids that help patients weigh procedural options against their goals of care.

Shared decision making, though less visible than registries, has been a quiet cornerstone of the TAVR quality framework. Because many candidates are elderly and managing multiple chronic conditions, the choice between transcatheter and surgical replacement, or between intervention and conservative management, depends heavily on individual values, frailty, and life circumstances. Formal decision aids and documented patient-physician conversations were built into prior coverage requirements precisely to ensure that expanded access reflects informed patient preference rather than procedural availability alone.

The societies’ emphasis on health care value also reflects a broader shift in cardiovascular policy toward weighing cost against measurable benefit. With TAVR now among the most common valve interventions performed in the United States, even modest differences in complication rates, length of stay, or device selection carry substantial aggregate economic consequences, reinforcing why continued outcomes reporting remains central to the field’s stewardship.

Subject of Research: Medicare national coverage determination for transcatheter aortic valve replacement and the quality standards supporting its expanded use

Article Title: Joint Statement from the American College of Cardiology, The Society of Thoracic Surgeons, and the Society for Cardiovascular Angiography & Interventions on transcatheter aortic valve replacement national coverage determination

Article References: Joint Statement from the American College of Cardiology, The Society of Thoracic Surgeons, and the Society for Cardiovascular Angiography & Interventions on transcatheter aortic valve replacement national coverage determination. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: TAVR, transcatheter aortic valve replacement, Medicare coverage, CMS, aortic stenosis, Heart Team, TVT Registry, American College of Cardiology, Society of Thoracic Surgeons, SCAI, quality monitoring, structural heart disease